<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29474" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Steatorrhea</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Azer</surname>
            <given-names>Samy A.</given-names>
          </name>
          <aff>King Saud University, King Khalid UH</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sankararaman</surname>
            <given-names>Senthilkumar</given-names>
          </name>
          <aff>University Hospitals Rainbow Babies &#x00026; Children&#x02019;s Hospital, Cleveland</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Samy Azer declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Senthilkumar Sankararaman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>16</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29474.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>The management of steatorrhea is complex and new approaches have been introduced. To achieve satisfactory outcomes, the basic and clinical aspects of steatorrhea must be clearly defined. This activity reviews the evaluation and management of steatorrhea and highlights the role of the interprofessional team in evaluating and improving care for patients suffering from steatorrhea.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of steatorrhea.</p></list-item><list-item><p>Describe the clinical features of steatorrhea.</p></list-item><list-item><p>Review the management of steatorrhea.</p></list-item><list-item><p>Identify interprofessional team strategies for improving care coordination and outcomes in patients suffering from steatorrhea.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29474&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29474">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29474.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The definition of steatorrhea is an increase&#x000a0;in fat excretion in the&#x000a0;stools. Steatorrhea is one of the clinical features of fat malabsorption and&#x000a0;noted in many conditions&#x000a0;such as exocrine pancreatic insufficiency (EPI), celiac disease, and&#x000a0;tropical sprue.&#x000a0;An increase in the&#x000a0;fat content of&#x000a0;stools results in the production of pale, large volume,&#x000a0;malodorous, loose stools. Screening for steatorrhea may be carried out by examining stool samples for&#x000a0;the presence of fat&#x000a0;by Sudan III staining. However, quantitative fecal fat estimation is&#x000a0;required to&#x000a0;confirm the diagnosis.</p>
        <p>Among the macronutrients, digestion and absorption of fat involve a complex mechanism. Fat absorption requires bile acids, digestive enzymes, and a normally functioning small intestinal mucosa. Dietary lipids, mostly as triacylglycerols,&#x000a0;are initially emulsified by bile&#x000a0;acids&#x000a0;and then hydrolyzed by the pancreatic lipases and colipases into free fatty acids and monoglycerides. In the proximal small bowel, these hydrolyzed lipids form micelles by the action of bile acids. The&#x000a0;micelles are then absorbed across the intestinal villi and transported as chylomicrons via the intestinal lymphatics. Therefore, any&#x000a0;defects in the availability or function&#x000a0;of bile acids, pancreatic digestive enzymes, or absorptive villi&#x000a0;will lead to steatorrhea.<xref ref-type="bibr" rid="article-29474.r1">[1]</xref></p>
      </sec>
      <sec id="article-29474.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The causes of steatorrhea are numerous and subclassified under three&#x000a0;broad categories:</p>
        <list list-type="order">
          <list-item>
            <p>Conditions leading to exocrine pancreatic insufficiency (EPI)</p>
          </list-item>
          <list-item>
            <p>Bile acid deficiency states</p>
          </list-item>
          <list-item>
            <p>Diseases affecting the&#x000a0;small intestine.</p>
          </list-item>
        </list>
        <p>Most notable&#x000a0;disorders&#x000a0;in each category are&#x000a0;given below<xref ref-type="bibr" rid="article-29474.r2">[2]</xref><xref ref-type="bibr" rid="article-29474.r3">[3]</xref><xref ref-type="bibr" rid="article-29474.r4">[4]</xref><xref ref-type="bibr" rid="article-29474.r5">[5]</xref><xref ref-type="bibr" rid="article-29474.r6">[6]</xref><xref ref-type="bibr" rid="article-29474.r7">[7]</xref><xref ref-type="bibr" rid="article-29474.r8">[8]</xref><xref ref-type="bibr" rid="article-29474.r9">[9]</xref><xref ref-type="bibr" rid="article-29474.r10">[10]</xref><xref ref-type="bibr" rid="article-29474.r11">[11]</xref>:</p>
        <list list-type="order">
          <list-item>
            <p><italic toggle="yes">EPI </italic>due to&#x000a0;chronic pancreatitis, cystic fibrosis (CF), and conditions resulting in pancreatic duct obstruction or resection of the&#x000a0;pancreas&#x000a0;(e.g., pancreatic tumors)</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Bile acid deficiency </italic>either due&#x000a0;to cholestasis e.g. primary biliary cirrhosis,&#x000a0;currently referred to as primary biliary cholangitis&#x000a0;(PBC), primary sclerosing cholangitis (PSC), or&#x000a0;inability to&#x000a0;absorb&#x000a0;bile acids&#x000a0;in the distal&#x000a0;ileum resulting in diminished bile acid pool e.g. ileal resection or&#x000a0;Crohn disease of the ileum or deconjugation of bile acids e.g., small&#x000a0;intestinal bacterial overgrowth (SIBO)</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Diseases affecting&#x000a0;proximal&#x000a0;small intestines </italic>such as celiac disease, tropical sprue, giardiasis, Whipple disease, lymphoma, amyloidosis, SIBO, and HIV enteropathy</p>
          </list-item>
        </list>
        <p><italic toggle="yes">&#x000a0;</italic>Other rare&#x000a0;causes of steatorrhea include&#x000a0;lipase inhibitors such as orlistat, Zollinger-Ellison syndrome (increased production of gastric acid inactivates the pH-sensitive&#x000a0;pancreatic lipases), and graft-versus-host disease.<xref ref-type="bibr" rid="article-29474.r3">[3]</xref></p>
      </sec>
      <sec id="article-29474.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>In the&#x000a0;early stages, steatorrhea may be unrecognized by many patients due to minimal or nonspecific presenting symptoms. Therefore, the&#x000a0;exact&#x000a0;prevalence&#x000a0;and incidence of steatorrhea&#x000a0;are challenging to estimate and often go underreported. Also, the epidemiology of steatorrhea&#x000a0;depends on the epidemiology of&#x000a0;various&#x000a0;underlying causes, which is a topic of the discussion below.</p>
        <p>In adults, chronic pancreatitis is the most common cause of EPI. Chronic pancreatitis&#x000a0;has an annual&#x000a0;incidence of approximately 4 per 100000 persons and a prevalence of about 42 per 100000 individuals in the&#x000a0;U.S.<xref ref-type="bibr" rid="article-29474.r12">[12]</xref>&#x000a0;In children,&#x000a0;CF accounts for most cases of EPI.&#x000a0;CF is the most common lethal autosomal recessive condition affecting the White population.<xref ref-type="bibr" rid="article-29474.r13">[13]</xref> The approximate prevalence of CF&#x000a0;is&#x000a0;1 in 3000 births. About 85% of CF patients&#x000a0;have pancreatic insufficiency.<xref ref-type="bibr" rid="article-29474.r13">[13]</xref></p>
        <p>The prevalence of celiac disease is on the rise, and a recent study reported a global seroprevalence of 1.4%.<xref ref-type="bibr" rid="article-29474.r14">[14]</xref>&#x000a0;Also, there are differences in the prevalence depending on geographical location. Reports of a biopsy-proven celiac disease show lower prevalence rates in South America and Africa and higher rates in Europe and Oceania.<xref ref-type="bibr" rid="article-29474.r14">[14]</xref> For example, in Europe, Germany has a lower prevalence of celiac disease, and the highest prevalence was in Sweden and Finland.<xref ref-type="bibr" rid="article-29474.r14">[14]</xref>&#x000a0;Celiac disease has a&#x000a0;higher prevalence in certain high-risk groups such as type 1 diabetes mellitus, Down syndrome, Turner syndrome, IgA deficiency, William syndrome, and in first-degree relatives of celiac disease.<xref ref-type="bibr" rid="article-29474.r8">[8]</xref><xref ref-type="bibr" rid="article-29474.r15">[15]</xref></p>
        <p>Based on a study from the&#x000a0;Netherlands, PBC had an incidence of 1.1 per 100000 (male to female ratio&#x000a0;was 1 to 6.3), and the point prevalence was 13.2 per 100000 individuals in 2008.<xref ref-type="bibr" rid="article-29474.r16">[16]</xref> Another study from the U.S. reported an overall&#x000a0;incidence of PBC as&#x000a0;2.7 per 100000 person-years and age and sex-adjusted&#x000a0;prevalence of 40 per 100000 with a&#x000a0;similar female predilection.<xref ref-type="bibr" rid="article-29474.r17">[17]</xref>&#x000a0;PSC has a prevalence rate depending on the geographical&#x000a0;location. A systematic review reported the incidence and prevalence rates of PSC&#x000a0;ranging from 0 to 1.3 per 100000&#x000a0;people per year and 0 to 16 per 100000 people, respectively.<xref ref-type="bibr" rid="article-29474.r18">[18]</xref>&#x000a0;As there is no consensus on the definition of SIBO, its exact prevalence is unknown.<xref ref-type="bibr" rid="article-29474.r11">[11]</xref></p>
      </sec>
      <sec id="article-29474.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>EPI: Chronic exposure to alcohol is&#x000a0;the most common etiological factor&#x000a0;for chronic pancreatitis. The other notable&#x000a0;risk factors for chronic pancreatitis include predisposing genetic mutations (<italic toggle="yes">PRSS-1, SPINK-1, CFTR, CTRC),</italic> autoimmune pancreatitis, pancreatic duct obstruction, and chronic nicotine exposure.<xref ref-type="bibr" rid="article-29474.r19">[19]</xref> The exact&#x000a0;pathophysiological&#x000a0;pathways underlying chronic pancreatitis are unclear but may include&#x000a0;mechanisms such as&#x000a0;chronic ongoing parenchymal&#x000a0;inflammation with acinar cell destruction, and&#x000a0;ductal dysfunction, etc.<xref ref-type="bibr" rid="article-29474.r19">[19]</xref> The histopathological changes include pancreatic&#x000a0;atrophy&#x000a0;with fibrous scarring, which may be focal or diffuse.<xref ref-type="bibr" rid="article-29474.r20">[20]</xref></p>
        <p>CF is a multisystem disease as a result of mutations in the gene which&#x000a0;encodes&#x000a0;the&#x000a0;CF transmembrane conductance&#x000a0;regulator&#x000a0;(CFTR).<xref ref-type="bibr" rid="article-29474.r13">[13]</xref> In the pancreas, CFTR dysfunction results in thick viscous&#x000a0;secretions along with defective bicarbonate flow resulting in EPI.</p>
        <p>Cholestatic Diseases: The mechanisms underlying the development of chronic cholestatic liver diseases, including PBC and PSC, are not entirely understood. Both these&#x000a0;disorders are characterized by portal inflammation and progressive fibrosis and eventually resulting in end-stage liver disease. Here, the reduction in bile flow results in the accumulation of toxic bile products, which leads to biliary epithelial damage.<xref ref-type="bibr" rid="article-29474.r21">[21]</xref> This decrease in&#x000a0;bile reaching the&#x000a0;small&#x000a0;bowel interferes with fat absorption and causes&#x000a0;steatorrhea in these patients.</p>
        <p>Celiac Disease: It&#x000a0;is a chronic autoimmune-mediated&#x000a0;enteropathy related to exposure&#x000a0;to dietary gluten&#x000a0;in genetically susceptible individuals. The genes which encode for major histocompatibility complex (MHC) class II proteins HLA-DQ2 and HLA-DQ8 are&#x000a0;prerequisites for this disease.&#x000a0;Ingestion of gluten (specifically the gliadin&#x000a0;peptides from wheat, rye, and barley) by susceptible individuals, along with&#x000a0;some unknown trigger factors, leads to pathogenesis.<xref ref-type="bibr" rid="article-29474.r8">[8]</xref>&#x000a0;Gliadin polypeptides are resistant to degradation in the gastrointestinal tract and&#x000a0;can cross the small intestinal epithelial barrier. In the lamina propria,&#x000a0;these peptides get deamidated by local extracellular tissue transglutaminase (TTG).<xref ref-type="bibr" rid="article-29474.r8">[8]</xref> This deamidation increases the affinity of gliadin binding to the antigen-binding groove of HLA DQ2 or HLA DQ8 on antigen-presenting cells. Upon presentation to CD4+ T lymphocytes, the gliadin peptides&#x000a0;trigger an immune response causing local inflammation, which results in the destruction of villi. In addition to adaptive immune dysfunction, patients with celiac disease also&#x000a0;have defects in innate intestinal immunity. The histopathological changes include increased intraepithelial lymphocytes, intestinal&#x000a0;villous atrophy (blunting or flattening of the villi), and crypt hyperplasia (elongation of the crypts).<xref ref-type="bibr" rid="article-29474.r22">[22]</xref> These&#x000a0;changes&#x000a0;lead to the malabsorption of fats and fat-soluble vitamins.</p>
        <p>SIBO: Under physiological conditions,&#x000a0;several defense&#x000a0;mechanisms regulate the microbiota in the gastrointestinal tract and prevent small intestine bacterial overgrowth. The&#x000a0;significant factors in SIBO prevention&#x000a0;include immunoglobin A,&#x000a0;gastric acidity, bile, and&#x000a0;defensins.<xref ref-type="bibr" rid="article-29474.r23">[23]</xref> The aboral&#x000a0;peristalsis with migratory motor complexes&#x000a0;and an intact ileocaecal valve&#x000a0;also play a vital role in preventing SIBO.<xref ref-type="bibr" rid="article-29474.r23">[23]</xref>&#x000a0;Any&#x000a0;disturbances&#x000a0;in these&#x000a0;mechanisms could result in bacterial overgrowth.<xref ref-type="bibr" rid="article-29474.r23">[23]</xref><xref ref-type="bibr" rid="article-29474.r11">[11]</xref> Deconjugation of bile&#x000a0;acids causes fat malabsorption along with&#x000a0;other factors such as ongoing inflammation, increased intestinal permeability.<xref ref-type="bibr" rid="article-29474.r23">[23]</xref><xref ref-type="bibr" rid="article-29474.r11">[11]</xref></p>
      </sec>
      <sec id="article-29474.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with steatorrhea present with bulky, pale, foul-smelling oily stools. These fatty stools tend to float in the toilet bowl and often challenging to flush&#x000a0;as well. In the&#x000a0;early stages, steatorrhea may be asymptomatic and go unnoticed.&#x000a0;Patients also have other&#x000a0;nonspecific manifestations of fat malabsorption&#x000a0;such as chronic diarrhea, abdominal discomfort, bloating sensation,&#x000a0;and&#x000a0;weight loss.&#x000a0;Children may present with growth failure and delayed puberty.&#x000a0;In severe cases,&#x000a0;loss of subcutaneous&#x000a0;fat and muscle wasting may be evident. Manifestations of fat-soluble vitamin (A, D, E, and K)&#x000a0;deficiencies&#x000a0;can accompany fat malabsorption. Celiac patients can present with a variety of&#x000a0;extraintestinal signs such as anemia, oral ulcers, and&#x000a0;dermatitis herpetiformis rash. Abdominal pain is a predominant symptom in patients with chronic pancreatitis but also&#x000a0;reported in other conditions such as SIBO, inflammatory bowel disease,&#x000a0;and celiac disease.&#x000a0;CF patients have sinopulmonary manifestations. Jaundice, fatigue,&#x000a0;and pruritis are suggestive of cholestatic liver diseases such as PBC or PSC. Signs for end-stage liver disease such as splenomegaly, ascites can be noted in PBC or PSC.</p>
      </sec>
      <sec id="article-29474.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The diagnosis of steatorrhea is based on clinical findings, laboratory tests, and radiological images. Endoscopy with&#x000a0;small intestinal biopsy,&#x000a0;liver biopsy,&#x000a0;and other specialized investigations may be needed to detect the exact&#x000a0;etiology of steatorrhea.</p>
        <p>Quantitative estimation of fecal fat (exceeding 7 g per 24 hours) is an essential first step for the diagnosis of steatorrhea. The standard method of fecal fat quantification is by calculating the coefficient of fat absorption (CFA).<xref ref-type="bibr" rid="article-29474.r24">[24]</xref> With&#x000a0;a standard&#x000a0;quantity of fat ingestion, CFA is the percentage of dietary&#x000a0;fat&#x000a0;that is absorbed.<xref ref-type="bibr" rid="article-29474.r24">[24]</xref> Patients should follow a strict diet for&#x000a0;five days containing 100 g of fats daily.<xref ref-type="bibr" rid="article-29474.r24">[24]</xref> Stools are collected in the last 72-hour for fecal fat estimation. CFA over 92% is considered normal.<xref ref-type="bibr" rid="article-29474.r24">[24]</xref> Even though accurate, this method is cumbersome and&#x000a0;unpleasant for most patients. For evaluation of EPI, fecal elastase may be&#x000a0;utilized&#x000a0;instead of the 72-hour fecal fat testing. A value of more than 200 mcg/g of stool is&#x000a0;considered normal; 100 to 200 mcg/g is indeterminate,&#x000a0;and&#x000a0;less than 100 mcg/g is abnormal&#x000a0;and indicative of EPI.&#x000a0;Here the&#x000a0;advantage is the&#x000a0;requirement of&#x000a0;a single stool sample.&#x000a0;However, in the&#x000a0;early stages of EPI, this test has a&#x000a0;lower sensitivity. Also, a&#x000a0;formed stool is necessary for testing. Otherwise, the fecal elastase could be falsely low due to dilution.</p>
        <p>For evaluation of&#x000a0;chronic pancreatitis, a plain abdominal radiograph may show pancreatic calcification, abdominal CT or MRI scans may reveal calcifications of chronic pancreatitis and ductal dilatation, magnetic resonance cholangiopancreatography (MRCP)&#x000a0;or endoscopic retrograde cholangiopancreatography (ERCP) can offer a more detailed evaluation of pancreatic parenchymal and ductal changes in chronic pancreatitis.<xref ref-type="bibr" rid="article-29474.r25">[25]</xref><xref ref-type="bibr" rid="article-29474.r26">[26]</xref> Similarly, MRCP, ERCP, and endoscopic ultrasound (EUS) are indispensable in the evaluation of pancreatic tumors.</p>
        <p>For evaluation of celiac disease, estimation of serum&#x000a0;tissue transglutaminase&#x000a0;IgA&#x000a0;antibodies (TTG-IgA) with total serum IgA is the recommended&#x000a0;screening test.<xref ref-type="bibr" rid="article-29474.r8">[8]</xref> IgA endomysial antibodies (EMA-IgA)&#x000a0;has the highest specificity and is an option if TTG-IgA is weakly positive.<xref ref-type="bibr" rid="article-29474.r8">[8]</xref> In patients with IgA deficiency, both TTG-IgA and EMA-IgA may be falsely low. In this population, TTG-IgG and deamidated gliadin peptide IgG (DGP-IgG) are the recommendations for screening.<xref ref-type="bibr" rid="article-29474.r8">[8]</xref> Patients with positive serological tests should be followed up with&#x000a0;duodenal biopsies for confirmation.<xref ref-type="bibr" rid="article-29474.r8">[8]</xref></p>
        <p>In patients suspected to have chronic liver disease, serum liver tests may reflect a cholestatic pattern, elevation of alkaline phosphatase and gamma-glutamyl transferase are&#x000a0;frequent findings in both PBC and PSC. AST,&#x000a0;ALT, and bilirubin may be normal or&#x000a0;elevated. Anti-mitochondrial antibodies are&#x000a0;noted in 90 to 95% of patients with PBC.<xref ref-type="bibr" rid="article-29474.r27">[27]</xref> Liver biopsy is not routinely needed for the&#x000a0;diagnosis&#x000a0;of PBC.&#x000a0;If done, a liver biopsy may show the destruction of interlobular bile ducts and cirrhotic changes in the&#x000a0;later stages.</p>
        <p>In PSC, magnetic resonance cholangiography (MRC)&#x000a0;is the preferred modality and may show a&#x000a0;multifocal narrowing of both intrahepatic and extrahepatic biliary ductal strictures. These strictures may be seen alternating with dilation, which is referred to&#x000a0;as the "beaded" appearance.<xref ref-type="bibr" rid="article-29474.r28">[28]</xref> ERCP or percutaneous transhepatic cholangiography&#x000a0;is also helpful to delineate the biliary anatomy in PSC but not routinely utilized for the&#x000a0;diagnosis due to their invasiveness.<xref ref-type="bibr" rid="article-29474.r28">[28]</xref> In PSC, a liver biopsy is not a routine test, and when done, may&#x000a0;demonstrate periductular fibrosis (onion skin fibrosis).<xref ref-type="bibr" rid="article-29474.r28">[28]</xref> Even though specific, this finding is infrequent.<xref ref-type="bibr" rid="article-29474.r28">[28]</xref> In PSC, a&#x000a0;liver biopsy may be helpful in&#x000a0;a few particular circumstances, such as for the&#x000a0;evaluation of small duct PSC and also to exclude coexistent autoimmune hepatitis, which is referred to&#x000a0;as overlap syndrome.<xref ref-type="bibr" rid="article-29474.r28">[28]</xref> About 80% of&#x000a0;patients with PSC have IBD.&#x000a0;Due to this strong association, if previously undiagnosed, a workup for IBD is recommended at the time of diagnosis of PSC.</p>
        <p>Endoscopy with direct aspiration and culture of the small intestinal contents was traditionally the gold standard test for SIBO.<xref ref-type="bibr" rid="article-29474.r11">[11]</xref> However, due to its invasive nature and lack of consensus on the definition regarding SIBO, this method is less preferred.<xref ref-type="bibr" rid="article-29474.r11">[11]</xref> Breath tests utilizing either glucose or lactulose&#x000a0;are commonly used in clinical practice.<xref ref-type="bibr" rid="article-29474.r11">[11]</xref></p>
      </sec>
      <sec id="article-29474.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment of steatorrhea depends on the underlying conditions which cause steatorrhea.</p>
        <list list-type="bullet">
          <list-item>
            <p>In patients with EPI, pancreatic enzyme replacement therapy (PERT)&#x000a0;is the&#x000a0;cornerstone of treatment.<xref ref-type="bibr" rid="article-29474.r29">[29]</xref></p>
          </list-item>
          <list-item>
            <p>Along with PERT,&#x000a0;patients with EPI&#x000a0;should receive normal to a high-fat diet&#x000a0;and fat-soluble vitamin supplementation.<xref ref-type="bibr" rid="article-29474.r3">[3]</xref> Fat restriction may improve the symptoms associated with steatorrhea but will worsen the nutritional status and is&#x000a0;no longer a recommendation.</p>
          </list-item>
          <list-item>
            <p>In patients with SIBO, an empiric trial of antibiotics is recommended.&#x000a0;In many institutions, rifaximin is preferable to other antibiotics such as&#x000a0;ciprofloxacin, metronidazole,&#x000a0;norfloxacin, doxycycline, and&#x000a0;amoxicillin-clavulanic acid.<xref ref-type="bibr" rid="article-29474.r23">[23]</xref><xref ref-type="bibr" rid="article-29474.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>In patients with celiac disease, diet-centered recommendations include a&#x000a0;strict life-long gluten-free diet, education about the disease, management of nutritional deficiencies, access to an advocacy group, and consultation with a skilled dietitian.<xref ref-type="bibr" rid="article-29474.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Ursodeoxycholic acid is the first-line treatment of choice for PBC.<xref ref-type="bibr" rid="article-29474.r30">[30]</xref> About 40% of patients may not respond to ursodeoxycholic acid&#x000a0;and may eventually need a&#x000a0;liver transplant.<xref ref-type="bibr" rid="article-29474.r30">[30]</xref></p>
          </list-item>
          <list-item>
            <p>Even though ursodeoxycholic acid is often used in PSC, medical therapy is not effective in curtailing the disease&#x000a0;progression. ERCP with stent dilatation is useful for symptomatic improvement in&#x000a0;biliary ductal strictures&#x000a0;in large intrahepatic or extrahepatic ducts.<xref ref-type="bibr" rid="article-29474.r28">[28]</xref> Liver transplantation is the definitive treatment for PSC&#x000a0;and,&#x000a0;post-transplant recurrence is not uncommon.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29474.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>When assessing a patient with steatorrhea, the following conditions must be considered and ruled out:</p>
        <list list-type="bullet">
          <list-item>
            <p>Alcoholic pancreatitis</p>
          </list-item>
          <list-item>
            <p>Hereditary&#x000a0;pancreatitis (mutations in&#x000a0;genes such as&#x000a0;<italic toggle="yes">PRSS-1, SPINK-1, CFTR, CTRC</italic>)</p>
          </list-item>
          <list-item>
            <p>Pancreatic insufficiency due to inherited conditions such as CF, Shwachman-Diamond syndrome, Pearson marrow syndrome,&#x000a0; and Johanson&#x02013;Blizzard syndrome</p>
          </list-item>
          <list-item>
            <p>Celiac disease</p>
          </list-item>
          <list-item>
            <p>Tropical sprue</p>
          </list-item>
          <list-item>
            <p>Chronic liver diseases such as PBC,&#x000a0;PSC</p>
          </list-item>
          <list-item>
            <p>Advanced pancreatic cancer</p>
          </list-item>
          <list-item>
            <p>Distal&#x000a0;ileal pathology (e.g., Crohn disease)&#x000a0;or resection</p>
          </list-item>
          <list-item>
            <p>Giardiasis</p>
          </list-item>
          <list-item>
            <p>Whipple disease</p>
          </list-item>
          <list-item>
            <p>SIBO</p>
          </list-item>
        </list>
        <p>&#x000a0;Following is the list of conditions that present with chronic diarrhea which can be mistaken for steatorrhea:</p>
        <list list-type="bullet">
          <list-item>
            <p>Irritable bowel syndrome</p>
          </list-item>
          <list-item>
            <p>Carbohydrate malabsorption (e.g., lactose intolerance, fructose malabsorption)</p>
          </list-item>
          <list-item>
            <p>Chronic laxative abuse</p>
          </list-item>
          <list-item>
            <p>Chronic or recurrent&#x000a0;gastrointestinal infections</p>
          </list-item>
          <list-item>
            <p>Withdrawal of opioids</p>
          </list-item>
          <list-item>
            <p>Endocrine causes (hyperthyroidism, Addisons disease, neuroendocrine tumors)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29474.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of steatorrhea depends on the underlying etiology. Steatorrhea due to exocrine pancreatic insufficiency and disorders of the small intestine like celiac disease, tropical sprue, or giardiasis has a good prognosis. But steatorrhea due to&#x000a0; CF and bile salt deficiencies like in PSC and PBC has a poor prognosis because of the progressive nature of underlying etiologies.</p>
      </sec>
      <sec id="article-29474.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Different causes of steatorrhea lead to different complications. Following are some complications that can occur due to steatorrhea:</p>
        <list list-type="bullet">
          <list-item>
            <p>Weight loss in adults and other consequences of malnutrition such as increased susceptibility to infections, and&#x000a0;increased morbidity and mortality from various disease states.&#x000a0;Additionally, in children, malnutrition results in growth failure and poor neurological development</p>
          </list-item>
          <list-item>
            <p>Deficiencies&#x000a0;of fat-soluble vitamins (A, D, E, and K)</p>
          </list-item>
          <list-item>
            <p>Poor bone health resulting in osteopenia, osteoporosis, and fractures&#x000a0;(CF, celiac disease)</p>
          </list-item>
          <list-item>
            <p>Iron deficiency anemia, zinc deficiency (celiac disease)</p>
          </list-item>
          <list-item>
            <p>Dermatitis herpetiformis,&#x000a0;non-Hodgkin lymphoma,&#x000a0;adenocarcinoma of the upper gastrointestinal tract (celiac disease)</p>
          </list-item>
          <list-item>
            <p>Megaloblastic anemia due to B12 deficiency&#x000a0;(in terminal ileum disease and SIBO)</p>
          </list-item>
          <list-item>
            <p>Pancreatic pseudocyst, ascites, splenic vein thrombosis, diabetes, pancreatic cancer (chronic pancreatitis)</p>
          </list-item>
          <list-item>
            <p>Seizure, osteopenia, ataxia, early bruising, headache, hyposplenism, and tetany (celiac disease)</p>
          </list-item>
          <list-item>
            <p>Cirrhosis, end-stage liver disease (PBC, PSC), malignancies such as cholangiocarcinoma, colon cancer in PSC</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29474.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patient education is very important in steatorrhea. Dietary counseling should be done by nutritionist regarding intake of fat and fat-soluble vitamins. It was advised earlier to decrease fat intake in patients with exocrine pancreatic insufficiency that helps in decreasing stool volume but it has been found that it causes malnutrition. So normal to high-fat diet with pancreatic enzyme replacement is advised in such patients. Similarly, dietary counseling in patients with celiac disease is essential.</p>
      </sec>
      <sec id="article-29474.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Untreated steatorrhea leads&#x000a0;to malnutrition and other&#x000a0;complications such as&#x000a0;fat-soluble vitamin deficiencies (A, D, E, and K). Identifying the cause of steatorrhea is vital for proper management and prevention of these&#x000a0;complications.<xref ref-type="bibr" rid="article-29474.r31">[31]</xref></p>
      </sec>
      <sec id="article-29474.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The diagnosis of steatorrhea is usually delayed for months&#x000a0;to years due to non-specific or minimal&#x000a0;presenting symptoms during the&#x000a0;early stages. An interprofessional team approach is often necessary for diagnosis, treatment, and follow-up. If steatorrhea is suspected clinically, the provider and nurse practitioner should refer the patient to a gastroenterologist for consultation. As numerous conditions could contribute to steatorrhea, a systematic evaluation is required to expedite the&#x000a0;diagnosis and to prevent further&#x000a0;complications. The team should also include specialty-trained nurses and pharmacists to assist with patient monitoring and education. The involvement of a skilled dietician is&#x000a0;indispensable for&#x000a0;enhancing the nutritional status&#x000a0;and limiting further malnutrition-related adverse outcomes.[Level V]</p>
      </sec>
      <sec id="article-29474.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29474&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29474">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/gut-health/steatorrhea/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=29474">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29474/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29474">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-29474.s16">
        <title>References</title>
        <ref id="article-29474.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Sabatino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lenti</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Corazza</surname>
                <given-names>GR</given-names>
              </name>
            </person-group>
            <article-title>Malabsorption and malabsorption tests: do they still matter?</article-title>
            <source>Dig Liver Dis</source>
            <year>2014</year>
            <month>May</month>
            <volume>46</volume>
            <issue>5</issue>
            <fpage>389</fpage>
            <page-range>389-90</page-range>
            <pub-id pub-id-type="pmid">24680500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29474.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zou</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>ZH</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Ning</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>ZS</given-names>
              </name>
            </person-group>
            <article-title>Risk Factors for Steatorrhea in Chronic Pancreatitis: A Cohort of 2,153 Patients.</article-title>
            <source>Sci Rep</source>
            <year>2016</year>
            <month>Feb</month>
            <day>15</day>
            <volume>6</volume>
            <fpage>21381</fpage>
            <pub-id pub-id-type="pmid">26877248</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29474.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shandro</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Nagarajah</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Poullis</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Challenges in the management of pancreatic exocrine insufficiency.</article-title>
            <source>World J Gastrointest Pharmacol Ther</source>
            <year>2018</year>
            <month>Oct</month>
            <day>25</day>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>39</fpage>
            <page-range>39-46</page-range>
            <pub-id pub-id-type="pmid">30397535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29474.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uchiyama</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kishi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Komatsu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Nagao</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ohhira</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kobashi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Lipid and Bile Acid Dysmetabolism in Crohn's Disease.</article-title>
            <source>J Immunol Res</source>
            <year>2018</year>
            <volume>2018</volume>
            <fpage>7270486</fpage>
            <pub-id pub-id-type="pmid">30402511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29474.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lanspa</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Go</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Dickson</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>DiMagno</surname>
                <given-names>EP</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis of steatorrhea in primary biliary cirrhosis.</article-title>
            <source>Hepatology</source>
            <year>1985</year>
            <season>Sep-Oct</season>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>837</fpage>
            <page-range>837-42</page-range>
            <pub-id pub-id-type="pmid">2411648</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29474.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holtmeier</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Leuschner</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.</article-title>
            <source>Digestion</source>
            <year>2001</year>
            <volume>64</volume>
            <issue>3</issue>
            <fpage>137</fpage>
            <page-range>137-50</page-range>
            <pub-id pub-id-type="pmid">11786661</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29474.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gasbarrini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lauritano</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Gabrielli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scarpellini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lupascu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ojetti</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gasbarrini</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Small intestinal bacterial overgrowth: diagnosis and treatment.</article-title>
            <source>Dig Dis</source>
            <year>2007</year>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>237</fpage>
            <page-range>237-40</page-range>
            <pub-id pub-id-type="pmid">17827947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29474.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lebwohl</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>PHR</given-names>
              </name>
            </person-group>
            <article-title>Coeliac disease.</article-title>
            <source>Lancet</source>
            <year>2018</year>
            <month>Jan</month>
            <day>06</day>
            <volume>391</volume>
            <issue>10115</issue>
            <fpage>70</fpage>
            <page-range>70-81</page-range>
            <pub-id pub-id-type="pmid">28760445</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29474.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Baloda</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gahlot</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vishnubathla</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ahuja</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Makharia</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Clinical, endoscopic, and histological differentiation between celiac disease and tropical sprue: A systematic review.</article-title>
            <source>J Gastroenterol Hepatol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>74</fpage>
            <page-range>74-83</page-range>
            <pub-id pub-id-type="pmid">30069926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29474.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poles</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Fuerst</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McGowan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rezaei</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mark</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Taing</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Anton</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>HIV-related diarrhea is multifactorial and fat malabsorption is commonly present, independent of HAART.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2001</year>
            <month>Jun</month>
            <volume>96</volume>
            <issue>6</issue>
            <fpage>1831</fpage>
            <page-range>1831-7</page-range>
            <pub-id pub-id-type="pmid">11421246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29474.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grace</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Whelan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Andreyev</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Review article: small intestinal bacterial overgrowth--prevalence, clinical features, current and developing diagnostic tests, and treatment.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>38</volume>
            <issue>7</issue>
            <fpage>674</fpage>
            <page-range>674-88</page-range>
            <pub-id pub-id-type="pmid">23957651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29474.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yadav</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Timmons</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Dierkhising</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Chari</surname>
                <given-names>ST</given-names>
              </name>
            </person-group>
            <article-title>Incidence, prevalence, and survival of chronic pancreatitis: a population-based study.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>106</volume>
            <issue>12</issue>
            <fpage>2192</fpage>
            <page-range>2192-9</page-range>
            <pub-id pub-id-type="pmid">21946280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29474.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paranjape</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Mogayzel</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Cystic fibrosis.</article-title>
            <source>Pediatr Rev</source>
            <year>2014</year>
            <month>May</month>
            <volume>35</volume>
            <issue>5</issue>
            <fpage>194</fpage>
            <page-range>194-205</page-range>
            <pub-id pub-id-type="pmid">24790073</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29474.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Arora</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Strand</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Leffler</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Catassi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Ahuja</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Makharia</surname>
                <given-names>GK</given-names>
              </name>
            </person-group>
            <article-title>Global Prevalence of Celiac Disease: Systematic Review and&#x000a0;Meta-analysis.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>6</issue>
            <fpage>823</fpage>
            <page-range>823-836.e2</page-range>
            <pub-id pub-id-type="pmid">29551598</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29474.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burden</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Langley-Evans</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Talley</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Coeliac disease: pathogenesis, prognosis and management.</article-title>
            <source>J Hum Nutr Diet</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>203</fpage>
            <page-range>203-4</page-range>
            <pub-id pub-id-type="pmid">24826997</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29474.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boonstra</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kunst</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Stadhouders</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Tuynman</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Poen</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>van Nieuwkerk</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Witteman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Hamann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Witteman</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Beuers</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Ponsioen</surname>
                <given-names>CY</given-names>
              </name>
              <collab>Epi PSC PBC study group</collab>
            </person-group>
            <article-title>Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study.</article-title>
            <source>Liver Int</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>34</volume>
            <issue>6</issue>
            <fpage>e31</fpage>
            <page-range>e31-8</page-range>
            <pub-id pub-id-type="pmid">24387641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29474.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Lindor</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Locke</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Therneau</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Homburger</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Batts</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Yawn</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Petz</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Melton</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Dickson</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology and natural history of primary biliary cirrhosis in a US community.</article-title>
            <source>Gastroenterology</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>119</volume>
            <issue>6</issue>
            <fpage>1631</fpage>
            <page-range>1631-6</page-range>
            <pub-id pub-id-type="pmid">11113084</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29474.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boonstra</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Beuers</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Ponsioen</surname>
                <given-names>CY</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review.</article-title>
            <source>J Hepatol</source>
            <year>2012</year>
            <month>May</month>
            <volume>56</volume>
            <issue>5</issue>
            <fpage>1181</fpage>
            <page-range>1181-1188</page-range>
            <pub-id pub-id-type="pmid">22245904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29474.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kleeff</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Whitcomb</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Shimosegawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Esposito</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lerch</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Gress</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mayerle</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Drewes</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Rebours</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Akisik</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz</surname>
                <given-names>JED</given-names>
              </name>
              <name>
                <surname>Neoptolemos</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Chronic pancreatitis.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2017</year>
            <month>Sep</month>
            <day>07</day>
            <volume>3</volume>
            <fpage>17060</fpage>
            <pub-id pub-id-type="pmid">28880010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29474.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conwell</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Yadav</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Longnecker</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Mortele</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Kwon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lieb</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Toskes</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Gelrud</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>BU</given-names>
              </name>
              <name>
                <surname>Forsmark</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Vege</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>American Pancreatic Association Practice Guidelines in Chronic Pancreatitis: evidence-based report on diagnostic guidelines.</article-title>
            <source>Pancreas</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>43</volume>
            <issue>8</issue>
            <fpage>1143</fpage>
            <page-range>1143-62</page-range>
            <pub-id pub-id-type="pmid">25333398</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29474.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mattner</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Impact of Microbes on the Pathogenesis of Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC).</article-title>
            <source>Int J Mol Sci</source>
            <year>2016</year>
            <month>Nov</month>
            <day>09</day>
            <volume>17</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">27834858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29474.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lindfors</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ciacci</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kurppa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lundin</surname>
                <given-names>KEA</given-names>
              </name>
              <name>
                <surname>Makharia</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Mearin</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Verdu</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Kaukinen</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Coeliac disease.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2019</year>
            <month>Jan</month>
            <day>10</day>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <pub-id pub-id-type="pmid">30631077</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29474.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghoshal</surname>
                <given-names>UC</given-names>
              </name>
              <name>
                <surname>Ghoshal</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Small Intestinal Bacterial Overgrowth and Other Intestinal Disorders.</article-title>
            <source>Gastroenterol Clin North Am</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>46</volume>
            <issue>1</issue>
            <fpage>103</fpage>
            <page-range>103-120</page-range>
            <pub-id pub-id-type="pmid">28164845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29474.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lindkvist</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Dom&#x000ed;nguez-Mu&#x000f1;oz</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Clinical, anthropometric and laboratory nutritional markers of pancreatic exocrine insufficiency: Prevalence and diagnostic use.</article-title>
            <source>Pancreatology</source>
            <year>2015</year>
            <season>Nov-Dec</season>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>589</fpage>
            <page-range>589-97</page-range>
            <pub-id pub-id-type="pmid">26243045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29474.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Gils</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Brand</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>de Boer</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Mulder</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Bouma</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Gastrointestinal diseases and their oro-dental manifestations: Part 3: Coeliac disease.</article-title>
            <source>Br Dent J</source>
            <year>2017</year>
            <month>Jan</month>
            <day>27</day>
            <volume>222</volume>
            <issue>2</issue>
            <fpage>126</fpage>
            <page-range>126-129</page-range>
            <pub-id pub-id-type="pmid">28126998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29474.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Durie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Baillargeon</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Bouchard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Donnellan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zepeda-Gomez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Teshima</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of pancreatic exocrine insufficiency (PEI) in primary care: consensus guidance of a Canadian expert panel.</article-title>
            <source>Curr Med Res Opin</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-33</page-range>
            <pub-id pub-id-type="pmid">28985688</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29474.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bader</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Beavers</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Semelka</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>MR imaging features of primary sclerosing cholangitis: patterns of cirrhosis in relationship to clinical severity of disease.</article-title>
            <source>Radiology</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>226</volume>
            <issue>3</issue>
            <fpage>675</fpage>
            <page-range>675-85</page-range>
            <pub-id pub-id-type="pmid">12616016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29474.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fricker</surname>
                <given-names>ZP</given-names>
              </name>
              <name>
                <surname>Lichtenstein</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Primary Sclerosing Cholangitis: A Concise Review of Diagnosis and Management.</article-title>
            <source>Dig Dis Sci</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>64</volume>
            <issue>3</issue>
            <fpage>632</fpage>
            <page-range>632-642</page-range>
            <pub-id pub-id-type="pmid">30725292</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29474.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clark</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Malabsorption Syndromes.</article-title>
            <source>Nurs Clin North Am</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>53</volume>
            <issue>3</issue>
            <fpage>361</fpage>
            <page-range>361-374</page-range>
            <pub-id pub-id-type="pmid">30100002</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29474.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santiago</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Scheinberg</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Cholestatic liver diseases: new targets, new therapies.</article-title>
            <source>Therap Adv Gastroenterol</source>
            <year>2018</year>
            <volume>11</volume>
            <fpage>1756284818787400</fpage>
            <pub-id pub-id-type="pmid">30159035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29474.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramos</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Figueir&#x000ea;do</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Aguiar</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Almeida</surname>
                <given-names>Cde G</given-names>
              </name>
              <name>
                <surname>Mendes</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Souza</surname>
                <given-names>EL</given-names>
              </name>
            </person-group>
            <article-title>Celiac Disease and Cystic Fibrosis: Challenges to Differential Diagnosis.</article-title>
            <source>Folia Med (Plovdiv)</source>
            <year>2016</year>
            <season>Apr-Jun</season>
            <volume>58</volume>
            <issue>2</issue>
            <fpage>141</fpage>
            <page-range>141-7</page-range>
            <pub-id pub-id-type="pmid">27552792</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
